Biotech News

Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)

Fennec Pharmaceuticals Inc. (FENC)Fennec Pharmaceuticals Inc.2025-12-26 22:44 ESTCompany update

NEW YORK , Dec. 26, 2025 (GLOBE NEWSWIRE) -- Southpoint Capital Advisors LP (“Southpoint”), acting on behalf of certain Southpoint funds for which it serves as investment manager, announces that on December 24, 2025 , pursuant to securities laws, it disposed of beneficial ownership of 1,000,000

Fennec Pharmaceuticals Inc.

Ototoxicity Prevention Company Fennec Pharmaceuticals commercializes PEDMARK, a sodium thiosulfate formulation designed to reduce permanent hearing loss caused by cisplatin chemotherapy. Pediatric Commercial Foundation PEDMARK is approved for pediatric patients with localized, non-metastatic solid tumors. Fennec supports adoption through...

Recent company news

FENCFennec Pharmaceuticals Inc.2026-08-11 11:01 EST

Stock data

Close: 11.29 USD
Market cap: 346.68M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)

Related news

Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals

Fennec Pharmaceuticals Inc.

Recent company news

Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Fennec Announces Results of Annual Meeting

Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting

Stock data